CDEK
← All drugs Report issue

insulin icodec

Recombinant proteinexperimental

Clinical trial activity

23 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
15
Phase 3
15
Phase 4
1

Earliest trial started Oct 16, 2020 (NCT04582448)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07165223Phase 3Oct 17, 2025Gan and Lee Pharmaceuticals, USA
NCT07112339Phase 4Aug 15, 2025Novo Nordisk
NCT07076199Phase 3Aug 11, 2025Novo Nordisk
NCT06340854Phase 3Apr 19, 2024Novo Nordisk
NCT06288412Phase 1Feb 26, 2024Novo Nordisk
NCT06269107Phase 3Feb 15, 2024Novo Nordisk
NCT05813912Phase 3Sep 22, 2023Novo Nordisk
NCT05790681Phase 1Apr 25, 2023Novo Nordisk
NCT05823948Phase 3Apr 11, 2023Novo Nordisk
NCT05435677Phase 1Jun 22, 2022Novo Nordisk
NCT05352815Phase 3Jun 1, 2022Novo Nordisk
NCT05259033Phase 3Apr 11, 2022Novo Nordisk
NCT05013229Phase 3Nov 30, 2021Novo Nordisk
NCT04880850Phase 3May 14, 2021Novo Nordisk
NCT04848480Phase 3Apr 30, 2021Novo Nordisk
NCT04857398Phase 1Apr 28, 2021Novo Nordisk
NCT04795531Phase 3Mar 24, 2021Novo Nordisk
NCT04770532Phase 3Mar 5, 2021Novo Nordisk
NCT04760626Phase 3Mar 1, 2021Novo Nordisk
NCT04597697Phase 1Jan 18, 2021Novo Nordisk
Showing 20 of 23 trials
Page 1 / 2

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Novo NordiskFor profit222232020
Gan and Lee Pharmaceuticals, USAFor profit1112025
2 organizations
Page 1 / 1